Galderma Group AG, the Swiss dermatology company, plans to add two members to its board and said chief financial officer Luigi La Corte is leaving for "a significant new opportunity." La Corte will stay on during the transition to ensure a smooth handover. Galderma will share succession details later. The board proposes electing Rosalind Brewer and Petra Rumpf, citing their leadership and governance experience in consumer-facing businesses, healthcare, medtech, and life sciences. Brewer would also join the Compensation Committee. Director Sherilyn McCoy is stepping down after seven years because of conflicting obligations. The board wants to raise its maximum size from 10 to 11 members. Shareholders will vote at a virtual extraordinary general meeting on December 3, 2026, at 14:00 CET.

SMI-listed Galderma stock: how much profit an investment in Galderma a year ago would have generated. 10/30/26, 10:00 a.m. That would have been the profit from an early investment in Galderma shares. On 10/30/2025, Galderma shares were traded on the SWX exchange. Galderma shares ended that trading day at CHF 147.50. If an investor had invested CHF 1,000 in the Galderma share at that time, they would now hold 6.780 Galderma shares. Since the value of one security on 10/29/2026 was CHF 189.70 (closing level), the original investment would now be worth CHF 1,286.10. That corresponds to an increase of 28.61 percent. Galderma's market value recently amounted to CHF 44.22 billion. The first trading day of the Galderma share on the SWX exchange was 03/22/2024. The Galderma share began its first trading day at CHF 61.00. Please note that stock splits and dividend payments are not taken into account in the above calculation. Finanzen.net editorial team Selected leveraged products on Galderma. With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired leverage and we will show you suitable open-end products on Galderma. Name | Leverage | KO | Issuer Turbo long on Galderma Group AG | 4.51 | 149.10 | Morgan Stanley Mini future long on Galderma Group AG | 4.22 | 160.18 | Morgan Stanley Turbo long on Galderma Group AG | 4.01 | 144.09 | Morgan Stanley Mini future long on Galderma Group AG | 3.56 | 150.69 | Morgan Stanley Turbo long on Galderma Group AG | 3.53 | 137.08 | Morgan Stanley You can obtain the base prospectus as well as the final terms and the key information documents here: MN6T0E, MR9T88, MN617V, MR85HB, MM4UH9. Please also note the further information** on this advertisement. Risk notice: on average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.